55-06-1 Usage
Description
Liothyronine sodium, also known as L-3,3',5-Triiodothyronine sodium salt, is an endocrine hormone produced by the thyroid gland and is considered an active thyroid hormone at the cellular level. It is thought to be more active than levothyroxine and has a rapid onset and short duration of action. Liothyronine sodium is a white to beige powder and is used in the treatment of hypothyroidism, particularly in cases of hypothyroid coma.
Uses
Used in Pharmaceutical Industry:
Liothyronine sodium is used as a medication for the treatment of hypothyroidism, as it helps in increasing the rates of protein synthesis, stimulating the breakdown of cholesterol, and affecting embryonic development. It is also used in cases of hypothyroid coma.
Used in Metabolic Homeostasis:
Liothyronine sodium is used as a hormone involved in the maintenance of metabolic homeostasis, as it is one of the hormones produced by the thyroid gland and is also produced in peripheral tissues as the active metabolite of Thyroxine.
Used in Cell Culture:
In cell culture, Liothyronine sodium is used as a regulator for cell differentiation and protein expression, as it plays a role in the regulation of these processes at the cellular level.
Used as a Cytochrome P450 Inhibitor:
Liothyronine sodium is used as an inhibitor of cytochrome P450, which is a group of enzymes involved in the metabolism of drugs and other substances in the body.
Used as a Calcium Antagonist:
Liothyronine sodium is used as a calcium antagonist, which helps in blocking the entry of calcium ions into cells, thus having potential applications in the treatment of certain cardiovascular conditions.
Used as a Local Anesthetic:
Liothyronine sodium is used as a local anesthetic, providing pain relief during medical procedures by temporarily blocking nerve conduction.
Brand Names:
Cytomel (King) and Triostat (Jones) are some of the brand names under which Liothyronine sodium is marketed.
Originator
Cytomel,SKF,US,1956
Indications
Liothyronine sodium (Cytomel) is the sodium salt of the
naturally occurring levorotatory isomer of T3. Liothyronine
is generally not used for maintenance thyroid
hormone replacement therapy because of its short
plasma half-life and duration of action. The use of T3
alone is recommended only in special situations, such as
in the initial therapy of myxedema and myxedema coma
and the short-term suppression of TSH in patients undergoing
surgery for thyroid cancer. The use of T3 alone
may also be useful in patients with the rare condition of
5'-deiodinase deficiency who cannot convert T4 to T3.
Manufacturing Process
The 3,5-diiodo compound used as a starting material is a known material and
may be prepared by the method in British Patents 643,089 and 671,070 and
in the Journal of the Chemical Society, London, 1949, page 3424.Synthesis: L-diiodo thyronine (1.05 g) is dissolved in ammonia (specific
gravity 0.880) (40 ml) and methanol (40 ml) and iodinated slowly with
shaking with N-iodine in KI solution at room temperature. After iodination,most of the ammonia and methanol are removed by evaporation under
diminished pressure, water is added to the original volume, the solution is
heated to 60°C and brought to pH 4 with hydrochloric acid. A crystalline
precipitate is obtained which after cooling to room temperature is collected
and washed with water. At this stage, the crude triiodo thyronine is
contaminated with thyroxine and a little unchanged diiodo thyronine.Purification: The crude precipitate is dissolved in boiling 2N HCl (300 ml) and
filtered from the relatively insoluble thyroxine hydrochloride. The hot filtrate is
brought to pH 4 with 5N NaOH and triiodo thyronine again separates; after
chilling at 0° to 4°C it is collected, washed with water and dried. The yield of
triiodo thyronine is 70 to 75% of the theoretical. This triiodo thyronine still
contains some thyroxine (about 10%).The final purification consists of chromatographic separation of thyroxine and
triiodo thyronine on a kieselguhr column using 20% chloroform in n-butanol
equilibrated with 0.5N NaOH as the developing solvent. 80 to 100 mg triiodo
thyronine is purified during each run on a 50 g kieselguhr column. Pure Ltriiodo thyronine has MP 236° to 237°C (dec.) and [α]D29.5° = +21.5 in a
4.75% solution in a mixture of 1 part of N HCl and 2 parts of ethanol.
Liothyronine is commonly used as the sodium salt.
Biochem/physiol Actions
3,3′,5′-Triiodo-L-thyronine (T3) is a thyroid hormone that increases rates of proteins synthesis, stimulates the breakdown of cholesterol, and effects embryonic development. In cell culture, T3 regulates cell differentiation and protein expression. The interaction of T3 with nonhistone proteins in the chromatin initiates the thyroid hormone activity. Thyroid hormones regulate the differentiation and development of tissues and affect a number of metabolic processes. The level of circulating T3 hormone is reduced in hypothyroidism.
Veterinary Drugs and Treatments
Because of its shorter duration of action, liothyronine is generally
not considered
the drug of first choice in treating hypothyroidism.
Infrequently, animals not responding to levothyroxine may respond
to liothyronine.
Check Digit Verification of cas no
The CAS Registry Mumber 55-06-1 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 5 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 55-06:
(4*5)+(3*5)+(2*0)+(1*6)=41
41 % 10 = 1
So 55-06-1 is a valid CAS Registry Number.
55-06-1Relevant articles and documents
3, 5-diiodo-O-[ 3-phenyl]-production of sulfate derivative of L-thyrosine (by machine translation)
-
Paragraph 0060, (2017/01/05)
The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L- tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.
